Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update
08 août 2018 16h22 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication
06 août 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the...
Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update
01 août 2018 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
26 juil. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...
Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update
09 mai 2018 16h20 HE
|
Otonomy, Inc.
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
08 mars 2018 16h24 HE
|
Otonomy, Inc.
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST ...
Otonomy to Present at Cowen and Company Health Care Conference
06 mars 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa
02 mars 2018 11h55 HE
|
Otonomy, Inc.
SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...
Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update
01 mars 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting
06 févr. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced seven data...